NCT07544056 2026-04-22
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
BeBetter Med Inc
Phase 2/3 Not yet recruiting
BeBetter Med Inc
Bristol-Myers Squibb
Shanghai Jiaolian Drug Research and Development Co., Ltd
ERYtech Pharma
Celgene